Buy Anavar 50

Produkt Beschreibung

1. Classification and Chemical Overview

Anavar 50 is an illicit, high-dose commercial trade formulation representing an oral solid dosage preparation of the synthetic anabolic-androgenic steroid (AAS) oxandrolone (chemically designated as $17\beta\text{-hydroxy-17}\alpha\text{-methyl-2-oxa-5}\alpha\text{-androstan-3-one}$). Structurally derived from dihydrotestosterone (DHT), the molecule incorporates two critical chemical modifications: the substitution of the carbon-2 atom in the phenanthrene A-ring with an oxygen atom (yielding a 2-oxa heterocyclic framework) and alkylation at the carbon-17 position with an alpha-oriented methyl group ($17\alpha\text{-alkylation}$). The 2-oxa core confers marked metabolic resistance against rapid intracellular deactivation by skeletal muscle $3\alpha\text{-hydroxysteroid dehydrogenase}$ ($3\alpha\text{-HSD}$), while the $17\alpha\text{-methyl}$ functional group provides steric protection against first-pass hepatic $17\beta\text{-hydroxy}$ oxidation, permitting high systemic oral bioavailability. Formulations bearing the brand designation “Anavar 50” are manufactured to deliver $50\text{ mg}$ of active oxandrolone per single tablet or capsule—a massive, supraphysiological strength that markedly exceeds historic human therapeutic single doses ($2.5\text{ to }10\text{ mg}$)—alongside standard pharmaceutical excipients such as microcrystalline cellulose, lactose, magnesium stearate, and colloidal silicon dioxide.

Within the United Kingdom regulatory framework, Anavar 50 possesses no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). While the trade name “Anavar” was historically registered by G.D. Searle & Co. for low-dose therapeutic preparations before its global discontinuation in 1989, any modern preparation designated “Anavar 50” is an unapproved, black-market product. Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, oxandrolone is categorized as a Class C, Schedule 4 (Part II) controlled drug. It is not catalogued in the British National Formulary (BNF) and is entirely absent from licensed NHS prescribing formularies. Preparations designated as Anavar 50 originate exclusively from illicit underground laboratories (UGLs) or unverified parallel grey-market distribution channels. Consequently, these products present critical clinical risks of substantial active pharmaceutical ingredient (API) dosage variability, heavy metal residues, microbiological non-sterility, or fraudulent substitution with cheaper, substantially more hepatotoxic alkylated androgens such as methandienone (Dianabol) or stanozolol.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of Anavar 50 is governed by selective intracellular androgen receptor activation, complete resistance to aromatisation, absence of peripheral $5\alpha$-reduction amplification, and profound nitrogen-retaining anabolism:

• Androgen Receptor (AR) Agonism and Myofibrillar Hypertrophy: Intact oxandrolone traverses target cell membranes to bind directly with high affinity to intracellular androgen receptors across skeletal myocytes, osteoblasts, and bone marrow stromal tissue. Because the 2-oxa ring substitution prevents intracellular enzymatic degradation by $3\alpha\text{-HSD}$, the ligand-receptor complex translocates into the nucleus, binding to specific androgen response elements (AREs) on genomic DNA. This drives RNA polymerase II-directed transcription, stimulating myofibrillar protein synthesis, promoting intracellular nitrogen retention, and upregulating skeletal muscle expression of insulin-like growth factor-1 (IGF-1). The anabolic-to-androgenic dissociation ratio is exceptionally high, estimated between $322:24$ und $630:24$ (relative to methyltestosterone at $100:100$).

• Complete Resistance to Aromatase: Because the steroid nucleus is fully $5\alpha\text{-reduced}$ and contains a 2-oxa substitution, oxandrolone is chemically incapable of interacting with the cytochrome P450 aromatase enzyme complex ($CYP19A1$). It undergoes zero metabolic conversion into oestrogenic metabolites ($17\beta\text{-oestradiol}$), precluding direct oestrogen-mediated subcutaneous water retention, true oestrogenic gynaecomastia, or oestrogen-dependent fluid retention.

• Absence of Peripheral $5\alpha\text{-Reductase}$ Amplification: The A/B ring junction of oxandrolone is already fully saturated in the $5\alpha\text{-configuration}$. Consequently, it does not serve as a substrate for $5\alpha\text{-reductase}$ isoenzymes (types 1, 2, or 3) and is not metabolized into a more potent androgenic species in peripheral target tissues such as the scalp, prostate gland, or pilosebaceous units. Target tissue responses are mediated directly by the parent molecule.

• Anticatabolic Glucocorticoid Antagonism: Oxandrolone functions as a competitive antagonist at the intracellular glucocorticoid receptor (GR), displacing endogenous cortisol within skeletal muscle. This suppresses ubiquitin-proteasome pathway degradation of contractile proteins, leading to profound preservation of lean body mass during states of caloric deprivation or metabolic stress.

• Profound Hypothalamic-Pituitary-Gonadal (HPG) Axis Suppression: Although low-dose oxandrolone is frequently mischaracterized in consumer circles as non-suppressive, a massive single dose of $50\text{ mg}$ exerts potent negative feedback inhibition at the hypothalamic arcuate nucleus and anterior pituitary gonadotrophs. Supraphysiological systemic titers suppress gonadotropin-releasing hormone (GnRH), luteinising hormone (LH), and follicle-stimulating hormone (FSH), leading to rapid, profound shutdown of endogenous testicular testosterone production.

3. Approved UK Clinical Indications and Therapeutic Scope

Anavar 50 possesses no approved clinical indications in the United Kingdom. No randomized, double-blind, multicentre Phase I–III clinical trials conforming to MHRA statutory criteria have evaluated a $50\text{ mg}$ single-unit formulation for safety, tolerability, or therapeutic efficacy.

The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate Anavar 50 into any clinical pathway. It is absent from clinical guidelines governing severe burns care, chronic obstructive pulmonary disease, chronic kidney disease wasting, or paediatric growth disorders. In authorized overseas jurisdictions and specialist tertiary care, lower therapeutic doses of pharmaceutical-grade oxandrolone ($2.5\text{ to }20\text{ mg/day}$) have held orphan approvals for:

• Adjunctive reversal of severe catabolic protein loss following extensive thermal injury (burns), major surgical trauma, or chronic infections.

• Counteracting glucocorticoid-induced muscle wasting during prolonged systemic corticosteroid administration.

• Promoting linear growth in paediatric female patients with confirmed Turner syndrome (concomitant with recombinant human growth hormone).

• Palliative treatment of severe cachexia and muscle wasting secondary to advanced human immunodeficiency virus (HIV) infection.

The practical use of Anavar 50 is confined entirely to illicit athletic performance enhancement, competitive bodybuilding, and forensic doping toxicology. In these unapproved settings, it is sought for:

• Accrual of dense skeletal muscle mass with zero fluid retention during pre-competition phases (“cutting”).

• Substantial augmentation of neuromuscular power output and absolute strength-to-weight ratios in weight-class-restricted athletic disciplines.

• Enhanced muscular recovery velocity between high-intensity training bouts.

Anavar 50 holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never be substituted for evidence-based, MHRA-licensed testosterone replacement therapy (TRT).

4. Pharmacokinetic Profile and Metabolic Fate

Because Anavar 50 is administered as a high-dose oral solid dosage form, its pharmacokinetic disposition is characterized by rapid intestinal uptake, hepatic resistance, and primarily renal elimination:

• Absorption: Oxandrolone exhibits high oral bioavailability ($>95\%$) due to its lipophilicity and structural $17\alpha\text{-alkylation}$, which prevents extensive presystemic intestinal and first-pass hepatic clearance. Ingestion of a $50\text{ mg}$ tablet produces high peak plasma concentrations ($C_{max}$) within 1 to 2 hours in a fasted state, although concurrent ingestion of high-fat meals can moderately delay the time to peak absorption ($T_{max}$).

• Distribution: Once absorbed into systemic circulation, oxandrolone binds extensively to plasma proteins, exhibiting an estimated binding fraction of $94\text{ to }97\%$, predominantly to human serum albumin with weak, non-specific binding to sex hormone-binding globulin (SHBG). Its displacement of endogenous steroids from SHBG transiently elevates the free, biologically active fraction of other circulating sex hormones. It possesses an apparent volume of distribution ($V_d$) ranging between $0.5\text{ and }0.8\text{ L/kg}$, distributing into skeletal muscle, hepatic parenchyma, adipose tissue, and traversing the blood-brain barrier.

• Biotransformation: Unlike non-alkylated androgens that undergo rapid hepatic microsomal breakdown, oxandrolone’s 2-oxa heterocyclic structure and $17\alpha\text{-methyl}$ substitution make it uniquely resistant to hepatic degradation. It does not rely heavily on the cytochrome P450 monooxygenase system. A significant fraction of the administered dose bypasses hepatic metabolism entirely; the portion that is metabolized undergoes slow hepatic epimerisation, hydroxylation, and Phase II conjugation into inactive polar metabolites, primarily $17\alpha\text{-oxandrolone}$ and 16-hydroxyoxandrolone.

• Elimination: Systemic elimination occurs predominantly through renal clearance. Uniquely among $17\alpha\text{-alkylated}$ steroids, approximately $25\text{ to }40\%$ of an administered oral dose of oxandrolone is excreted unchanged in the urine. The remainder is cleared in the urine as polar glucuronide and sulfate conjugates, with less than $3\text{ to }5\%$ eliminated in faeces via biliary secretion. The elimination half-life ($t_{1/2}$) in healthy adults ranges between 9 and 12 hours (extending up to 13 hours in elderly populations). At a $50\text{ mg}$ dosage, residual urinary metabolites remain detectable via gas chromatography-mass spectrometry (GC-MS) or LC-MS/MS anti-doping screens for several weeks to months following cessation.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect reported in athletic and non-medical contexts is a rapid accrual of lean skeletal muscle mass, increased muscular strength, and a vascular physique devoid of subcutaneous fluid retention. However, administering a massive $50\text{ mg}$ dose of an oral $17\alpha\text{-alkylated}$ steroid produces severe, multi-system adverse effects:

• Cardiovascular and Atherogenic Lipid Toxicity:

  • Severe atherogenic dyslipidaemia: oral $17\alpha\text{-alkylated}$ steroids exert potent, direct stimulatory effects on hepatic triglyceride lipase. At a $50\text{ mg}$ daily dosage, oxandrolone causes catastrophic suppression of high-density lipoprotein cholesterol (HDL-C; routinely plunging by $60\text{ to }85\%$, frequently falling below $0.2\text{ to }0.3\text{ mmol/L}$) and marked elevations in low-density lipoprotein cholesterol (LDL-C; rising by $40\text{ to }70\%$), dramatically accelerating arterial atherogenesis and coronary artery disease.

  • Systemic hypertension: secondary to vascular endothelial stiffness, increased vascular tone, and alterations in renal vascular resistance.

  • Subclinical myocardial remodeling: sustained exposure promotes pathological left ventricular concentric hypertrophy, microvascular ischaemia, and impaired myocardial diastolic relaxation.

  • Polycythaemia: stimulation of renal erythropoietin production elevates haematocrit ($>52\text{–}54\%$), increasing blood viscosity and thrombotic risk (stroke, pulmonary embolism, myocardial infarction).

• Hepatic Toxicity (Hepatotoxicity):

  • As an oral $17\alpha\text{-alkylated}$ compound, a $50\text{ mg}$ dose places substantial metabolic and excretory strain on hepatic parenchymal cells and biliary canaliculi. Chronic exposure regularly causes marked elevations in serum transaminases (ALT, AST) and gamma-glutamyl transferase (GGT).

  • Prolonged supraphysiological use carries verified risks of chronic intrahepatic cholestasis, peliosis hepatis (blood-filled cystic lesions in the liver parenchyma), hepatic adenomas, and, rarely, malignant hepatocellular carcinoma.

• Endocrine and Gonadal Axis Suppression:

  • Severe suppression of the HPG axis: negative feedback at the hypothalamus and pituitary downregulates LH and FSH secretion, resulting in testicular atrophy, azoospermia, and prolonged secondary hypogonadotrophic hypogonadism following drug withdrawal.

• Androgenic and Dermatological Effects:

  • Androgenic dermatopathy: despite its low androgenic rating, high-dose administration frequently triggers severe cystic acne (predominantly localized to the shoulders, upper back, and face) and accelerates androgenetic alopecia in genetically predisposed individuals.

  • Virilisation in Females: At a $50\text{ mg}$ dose, oxandrolone causes rapid, profound, and irreversible virilisation in females, including irreversible deepening of the vocal cords, clitoromegaly, severe hirsutism, facial hair growth, and chronic amenorrhoea.

• Renal and Metabolic Strain:

  • Elevated serum creatinine levels: secondary to both direct inhibition of creatinine breakdown/alterations in tubular handling and accelerated skeletal muscle turnover, which can confound laboratory assessment of estimated glomerular filtration rate (eGFR).

6. Contraindications, Drug Interactions, and Clinical Precautions

Given its non-approved clinical status, oral hepatotoxic structure, and marked atherogenic profile, Anavar 50 requires strict adherence to pharmacological contraindications and clinical harm-minimisation standards:

• Contraindications:

  • Absolute Contraindication in All Humans: The preparation is an illicit, unregulated chemical tablet lacking medicinal safety clearance.

  • Known or Suspected Malignancy: Absolute contraindication in prostate adenocarcinoma, male breast carcinoma, or any hormone-sensitive neoplasm; absolute contraindication in known or suspected active hepatic neoplasms.

  • Pre-existing Cardiovascular Disease: Absolute contraindication in severe coronary artery disease, history of myocardial infarction, cerebrovascular disease (stroke/TIA), uncontrolled hypertension, or chronic heart failure.

  • Significant Hepatic Impairment: Absolute contraindication in patients with baseline liver cirrhosis, active viral or autoimmune hepatitis, cholestatic liver disease, or baseline transaminases exceeding three times the upper limit of normal (ULN).

  • Severe Renal Impairment: Contraindicated in chronic kidney disease (CKD Stages 4–5) due to predominantly renal excretion of the active parent molecule.

  • Pregnancy and Lactation: Absolute contraindication; severe teratogenicity, fatal fetal harm, and profound irreversible masculinisation/virilisation of the female fetus.

  • Paediatric Population: Contraindicated in children and adolescents due to premature epiphyseal plate closure, stunting of adult stature, and precocious sexual development.

• Drug Interactions:

  • Oral Anticoagulants (e.g., Warfarin, DOACs): Oxandrolone significantly enhances patient sensitivity to oral anticoagulants by inhibiting hepatic clearance of warfarin and altering prothrombin complex synthesis. Severe, unpredictable elevations in the International Normalised Ratio (INR) and life-threatening haemorrhagic events can occur, requiring extreme clinical vigilance and substantial warfarin dose reductions.

  • Oral Hypoglycaemic Agents and Insulin: Anabolic steroids alter peripheral carbohydrate tolerance and increase insulin sensitivity; co-administration with metformin, sulfonylureas, or exogenous insulin can precipitate severe, unpredictable hypoglycaemic episodes, requiring close blood glucose monitoring.

  • Hepatotoxic Medications (e.g., Paracetamol, Methotrexate, Statins, Azole Antifungals): Concurrent use with other hepatotoxic substances exerts additive cytotoxic stress on hepatocytes, multiplying risks of severe drug-induced liver injury (DILI).

  • Other Anabolic-Androgenic Steroids: Stacking with other oral $17\alpha\text{-alkylated}$ steroids compounds hepatic parenchymal damage and accelerates severe lipid dysregulation.

• Clinical Precautions and Harm Minimisation:

  • Cardiovascular Alarm Symptoms (“Red Flags”): Patients presenting with crushing central chest pressure, acute exertional dyspnoea, sudden unilateral focal neurological deficits (facial droop, speech impairment), or acute unilateral lower limb swelling require immediate emergency (999/A&E) transfer.

  • Hepatic Alarm Signs: Emergence of clinical scleral or cutaneous jaundice, dark brown urine, pale acholic stools, persistent right upper quadrant pain, or intractable pruritus indicates acute cholestasis or severe hepatic injury, necessitating immediate drug cessation and urgent specialist hepatological admission.

  • Structured Diagnostic Workup for Illicit AAS Users: Clinicians encountering individuals actively using or discontinuing Anavar 50 should perform a comprehensive risk assessment: 12-lead ECG, blood pressure evaluation, full blood count (monitoring haematocrit), comprehensive lipid profile (total cholesterol, HDL-C, LDL-C, triglycerides), liver function tests (ALT, AST, ALP, GGT, bilirubin), renal function tests (urea, creatinine, eGFR, cystatin-C), and an early-morning endocrine panel (total testosterone, SHBG, LH, FSH, oestradiol).

  • Clinical Cessation Support: Clinicians should counsel patients directly and objectively on the systemic toxicities of unregulated UGL oral steroids, support structured drug cessation, and coordinate endocrine referral for the diagnosis and management of prolonged post-AAS hypogonadotrophic hypogonadism where clinically indicated.